Cargando…
Gliosarcoma with Systemic Metastasis Showing Favorable Response to Ifosfamide, Carboplatin, and Etoposide Chemotherapy: An Autopsy Case Report
Gliosarcoma is a rare malignant neoplasm. It accounts for approximately 2% of all glioblastomas. To date, there is no established treatment method for gliosarcoma, and a variety of therapies, such as surgical resection, radiotherapy, and chemotherapy, are typically employed. Here, we describe a pati...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Japan Neurosurgical Society
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9484818/ https://www.ncbi.nlm.nih.gov/pubmed/36186622 http://dx.doi.org/10.2176/jns-nmc.2022-0075 |
_version_ | 1784791954138071040 |
---|---|
author | NAKAGAKI, Yuki KAI, Keitaro KOMOHARA, Yoshihiro TAKEZAKI, Tatsuya KURODA, Junichiro SHINOJIMA, Naoki SHIMOMURA, Mari KAWAKAMI, Fumi MIKAMI, Yoshiki MUKASA, Akitake |
author_facet | NAKAGAKI, Yuki KAI, Keitaro KOMOHARA, Yoshihiro TAKEZAKI, Tatsuya KURODA, Junichiro SHINOJIMA, Naoki SHIMOMURA, Mari KAWAKAMI, Fumi MIKAMI, Yoshiki MUKASA, Akitake |
author_sort | NAKAGAKI, Yuki |
collection | PubMed |
description | Gliosarcoma is a rare malignant neoplasm. It accounts for approximately 2% of all glioblastomas. To date, there is no established treatment method for gliosarcoma, and a variety of therapies, such as surgical resection, radiotherapy, and chemotherapy, are typically employed. Here, we describe a patient with gliosarcoma who, despite multiple tumor metastases throughout the body, including the lungs and lymph nodes, achieved a relatively long survival due to salvage therapy with local irradiation and remarkably effective chemotherapy with low-dose ifosfamide, carboplatin, and etoposide therapy. When the patient died, we performed autopsy and confirmed the nature of the primary and metastatic tumor cells that had spread throughout the patient's body. Clinical and systemic histological studies also suggested the possibility of re-metastasis to the brain from systemic metastatic foci. Gliosarcoma appears to have characteristics similar to sarcoma as well as a higher risk of systemic metastasis. Therefore, a careful follow-up is necessary in such patients. |
format | Online Article Text |
id | pubmed-9484818 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | The Japan Neurosurgical Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-94848182022-10-01 Gliosarcoma with Systemic Metastasis Showing Favorable Response to Ifosfamide, Carboplatin, and Etoposide Chemotherapy: An Autopsy Case Report NAKAGAKI, Yuki KAI, Keitaro KOMOHARA, Yoshihiro TAKEZAKI, Tatsuya KURODA, Junichiro SHINOJIMA, Naoki SHIMOMURA, Mari KAWAKAMI, Fumi MIKAMI, Yoshiki MUKASA, Akitake NMC Case Rep J Case Report Gliosarcoma is a rare malignant neoplasm. It accounts for approximately 2% of all glioblastomas. To date, there is no established treatment method for gliosarcoma, and a variety of therapies, such as surgical resection, radiotherapy, and chemotherapy, are typically employed. Here, we describe a patient with gliosarcoma who, despite multiple tumor metastases throughout the body, including the lungs and lymph nodes, achieved a relatively long survival due to salvage therapy with local irradiation and remarkably effective chemotherapy with low-dose ifosfamide, carboplatin, and etoposide therapy. When the patient died, we performed autopsy and confirmed the nature of the primary and metastatic tumor cells that had spread throughout the patient's body. Clinical and systemic histological studies also suggested the possibility of re-metastasis to the brain from systemic metastatic foci. Gliosarcoma appears to have characteristics similar to sarcoma as well as a higher risk of systemic metastasis. Therefore, a careful follow-up is necessary in such patients. The Japan Neurosurgical Society 2022-08-26 /pmc/articles/PMC9484818/ /pubmed/36186622 http://dx.doi.org/10.2176/jns-nmc.2022-0075 Text en © 2022 The Japan Neurosurgical Society https://creativecommons.org/licenses/by-nc-nd/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives International License. |
spellingShingle | Case Report NAKAGAKI, Yuki KAI, Keitaro KOMOHARA, Yoshihiro TAKEZAKI, Tatsuya KURODA, Junichiro SHINOJIMA, Naoki SHIMOMURA, Mari KAWAKAMI, Fumi MIKAMI, Yoshiki MUKASA, Akitake Gliosarcoma with Systemic Metastasis Showing Favorable Response to Ifosfamide, Carboplatin, and Etoposide Chemotherapy: An Autopsy Case Report |
title | Gliosarcoma with Systemic Metastasis Showing Favorable Response to Ifosfamide, Carboplatin, and Etoposide Chemotherapy: An Autopsy Case Report |
title_full | Gliosarcoma with Systemic Metastasis Showing Favorable Response to Ifosfamide, Carboplatin, and Etoposide Chemotherapy: An Autopsy Case Report |
title_fullStr | Gliosarcoma with Systemic Metastasis Showing Favorable Response to Ifosfamide, Carboplatin, and Etoposide Chemotherapy: An Autopsy Case Report |
title_full_unstemmed | Gliosarcoma with Systemic Metastasis Showing Favorable Response to Ifosfamide, Carboplatin, and Etoposide Chemotherapy: An Autopsy Case Report |
title_short | Gliosarcoma with Systemic Metastasis Showing Favorable Response to Ifosfamide, Carboplatin, and Etoposide Chemotherapy: An Autopsy Case Report |
title_sort | gliosarcoma with systemic metastasis showing favorable response to ifosfamide, carboplatin, and etoposide chemotherapy: an autopsy case report |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9484818/ https://www.ncbi.nlm.nih.gov/pubmed/36186622 http://dx.doi.org/10.2176/jns-nmc.2022-0075 |
work_keys_str_mv | AT nakagakiyuki gliosarcomawithsystemicmetastasisshowingfavorableresponsetoifosfamidecarboplatinandetoposidechemotherapyanautopsycasereport AT kaikeitaro gliosarcomawithsystemicmetastasisshowingfavorableresponsetoifosfamidecarboplatinandetoposidechemotherapyanautopsycasereport AT komoharayoshihiro gliosarcomawithsystemicmetastasisshowingfavorableresponsetoifosfamidecarboplatinandetoposidechemotherapyanautopsycasereport AT takezakitatsuya gliosarcomawithsystemicmetastasisshowingfavorableresponsetoifosfamidecarboplatinandetoposidechemotherapyanautopsycasereport AT kurodajunichiro gliosarcomawithsystemicmetastasisshowingfavorableresponsetoifosfamidecarboplatinandetoposidechemotherapyanautopsycasereport AT shinojimanaoki gliosarcomawithsystemicmetastasisshowingfavorableresponsetoifosfamidecarboplatinandetoposidechemotherapyanautopsycasereport AT shimomuramari gliosarcomawithsystemicmetastasisshowingfavorableresponsetoifosfamidecarboplatinandetoposidechemotherapyanautopsycasereport AT kawakamifumi gliosarcomawithsystemicmetastasisshowingfavorableresponsetoifosfamidecarboplatinandetoposidechemotherapyanautopsycasereport AT mikamiyoshiki gliosarcomawithsystemicmetastasisshowingfavorableresponsetoifosfamidecarboplatinandetoposidechemotherapyanautopsycasereport AT mukasaakitake gliosarcomawithsystemicmetastasisshowingfavorableresponsetoifosfamidecarboplatinandetoposidechemotherapyanautopsycasereport |